Correspondence | Published:

Publications and patents in corporate venture–backed biotech

Nature Biotechnology volume 31, pages 495497 (2013) | Download Citation

Subjects

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Nat. Biotechnol. 30, 911–915 (2012).

  2. 2.

    Nat. Biotechnol. 30, 395–400 (2012).

  3. 3.

    J. Econ. Lit. 28, 1661–1707 (1990).

  4. 4.

    & Manage. Sci. 48, 44–60 (2002).

  5. 5.

    PricewaterhouseCoopers. Corporate venture capital activity on three-year upward trend. <> (2012).

  6. 6.

    Corporate venture funds boost biotech startups. <> (SFGate, 15 November 2011).

  7. 7.

    The Burrill Report 2, 10 (2012).

Download references

Acknowledgements

Funding from the Mack Center (the Wharton School) is greatly appreciated.

Author information

Affiliations

  1. Georgia State University, Atlanta, Georgia, USA.

    • Elisa Alvarez-Garrido
  2. London Business School, London, UK.

    • Gary Dushnitsky

Authors

  1. Search for Elisa Alvarez-Garrido in:

  2. Search for Gary Dushnitsky in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Elisa Alvarez-Garrido or Gary Dushnitsky.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1 and 2

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2569

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing